

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



杭州启明醫療器械股份有限公司  
**Venus Medtech (Hangzhou) Inc.**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 2500)**

**APPOINTMENT OF CHIEF FINANCIAL OFFICER  
AND  
CONTINUED SUSPENSION OF TRADING**

References are made to (i) the announcement of Venus Medtech (Hangzhou) Inc. (the “**Company**”) dated June 2, 2023 (the “**June 2 Announcement**”) in relation to, amongst others, the resignation of Mr. Haiyue Ma as a joint company secretary and the chief financial officer of the Company with effect from June 2, 2023; (ii) the announcement of the Company dated November 27, 2023 (the “**November 27 Announcement**”) in relation to, amongst others, further update on the provision of financial assistance; and (iii) the announcement of the Company dated December 27, 2023 in relation to, amongst others, the guidance for the resumption of trading in the shares of the Company (together with the June 2 Announcement and the November 27 Announcement, collectively referred to as the “**Announcements**”). Unless otherwise stated, capitalized terms used in this announcement shall bear the same meanings as those defined in the Announcements.

**APPOINTMENT OF CHIEF FINANCIAL OFFICER**

As disclosed in the June 2 Announcement, Mr. Haiyue Ma has resigned from his position of the chief financial officer of the Company with effect from June 2, 2023. Since June 2, 2023, the Company has not appointed a new chief financial officer. Subsequently, it was disclosed in the November 27 Announcement that the nomination committee of the Board has targeted to consider and recommend a new chief financial officer of the Company (the “**Chief Financial Officer**”) with appropriate qualifications to the Board by the end of April 2024. Since then, the Board has been considering a number of candidates recommended by the nomination committee of the Board for the position of the Chief Financial Officer.

The Board is pleased to announce that, Mr. Fei Wang (“**Mr. Wang**”) has been appointed as the Chief Financial Officer with effect from January 4, 2024. The biographical details of Mr. Wang are set out below:

**Fei Wang** (王飛), aged 46, has over 20 years of experience in finance and strategic planning. Mr. Wang previously served as the chief financial officer of 3SBio Inc. (三生製藥集團) (stock code: 1530.HK) from April 2020 to April 2023. Before that, Mr. Wang worked at AstraZeneca, as the chief financial officer of its China operation from January 2011 to October 2015 and as the director of finance of its respiration, immunology and inflammation department from January 2020 to April 2020. He served as an executive director and as chief financial officer of a Hong Kong listed company from March 2018 to December 2019.

Mr. Wang received a bachelor’s degree in management from Xinjiang University of Finance and Economics in 1999 and an MBA from Shanghai Jiao Tong University and Euromed Marseille Ecole de Management (now known as KEDGE) in 2012. Mr. Wang is a certified public accountant in the PRC.

The Board would like to express its warmest welcome to Mr. Wang on his new position in the Company.

#### **CONTINUED SUSPENSION OF TRADING**

Trading in the shares of the Company on the Stock Exchange has been suspended with effect from 9:00 a.m. on November 23, 2023 and will remain suspended until further notice.

**Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.**

By Order of the Board  
**Venus Medtech (Hangzhou) Inc.**  
**Mr. Lim Hou-Sen (Lin Haosheng)**  
*Executive Director*

Hangzhou, January 4, 2024

*As at the date of this announcement, the executive Directors are Mr. Lim Hou-Sen (Lin Haosheng), Mr. Liqiao Ma and Ms. Meirong Liu; the non-executive Directors are Mr. Ao Zhang and Mr. Wei Wang; and the independent non-executive Directors are Mr. Ting Yuk Anthony Wu, Mr. Wan Yee Joseph Lau and Mr. Chi Wai Suen.*